Invitation to the presentation of Calliditas´s interim report January - June 2024
Calliditas Therapeutics (CALT) has announced the upcoming release of its interim report for Q2 2024 (April - June) on Tuesday, August 13, 2024, at 07:00 a.m. CET. The report will be available in both Swedish and English. Following the release, the company will host a combined audio cast and telephone conference at 14:30 p.m. CET on the same day.
The presentation will feature CEO Renée Aguiar-Lucander, CFO Fredrik Johansson, CMO Richard Philipson, and President North America Maria Törnsén. Participants will have the opportunity to ask questions during the event, which will be conducted in English. Interested parties can join via webcast or conference call, with registration required for the latter.
Calliditas Therapeutics (CALT) ha annunciato la prossima pubblicazione del suo rapporto intermedio per il secondo trimestre del 2024 (aprile - giugno) che avverrà martedì 13 agosto 2024, alle 07:00 CET. Il rapporto sarà disponibile sia in svedese che in inglese. Dopo la pubblicazione, l'azienda terrà una conferenza audio e telefonica combinata alle 14:30 CET dello stesso giorno.
La presentazione includerà il CEO Renée Aguiar-Lucander, il CFO Fredrik Johansson, il CMO Richard Philipson e la Presidente Nord America Maria Törnsén. I partecipanti avranno l'opportunità di porre domande durante l'evento, che si svolgerà in inglese. Le parti interessate possono partecipare tramite webcast o chiamata conference, con registrazione necessaria per quest'ultima.
Calliditas Therapeutics (CALT) ha anunciado la próxima publicación de su informe interino para el segundo trimestre de 2024 (abril - junio) que será el martes 13 de agosto de 2024 a las 07:00 a.m. CET. El informe estará disponible en sueco e inglés. Tras la publicación, la compañía realizará una conferencia telefónica y de audio combinada a las 14:30 p.m. CET el mismo día.
La presentación contará con la CEO Renée Aguiar-Lucander, el CFO Fredrik Johansson, el CMO Richard Philipson y la Presidenta de América del Norte Maria Törnsén. Los participantes tendrán la oportunidad de hacer preguntas durante el evento, que se llevará a cabo en inglés. Las partes interesadas pueden unirse a través de un webcast o conferencia telefónica, siendo necesaria la registración para esta última.
Calliditas Therapeutics (CALT)는 2024년 2분기(4월 - 6월)에 대한 Interim Report를 2024년 8월 13일 화요일, 오전 7시 CET에 발표한다고 발표했습니다. 이 보고서는 스웨덴어와 영어로 제공될 예정입니다. 발표 후, 회사는 같은 날 오후 2시 30분 CET에 오디오 방송 및 전화 회의를 결합한 이벤트를 개최합니다.
발표에는 CEO Renée Aguiar-Lucander, CFO Fredrik Johansson, CMO Richard Philipson, 북미 사장 Maria Törnsén이 포함됩니다. 참가자는 영어로 진행되는 행사 동안 질문할 기회를 가질 수 있습니다. 관심이 있는 분들은 웹캐스트나 전화 회의에 참여할 수 있으며, 후자의 경우 등록이 필요합니다.
Calliditas Therapeutics (CALT) a annoncé la prochaine publication de son rapport intérimaire pour le deuxième trimestre de 2024 (avril - juin) qui aura lieu le mardi 13 août 2024, à 07h00 CET. Le rapport sera disponible en suédois et en anglais. Après la publication, la société organisera une conférence audio et téléphonique combinée à 14h30 CET le même jour.
La présentation mettra en vedette le PDG Renée Aguiar-Lucander, le directeur financier Fredrik Johansson, le directeur médical Richard Philipson et la présidente Amérique du Nord Maria Törnsén. Les participants auront l'occasion de poser des questions durant l'événement qui se déroulera en anglais. Les parties intéressées peuvent se joindre via un webcast ou une conférence téléphonique, l'inscription étant nécessaire pour cette dernière.
Calliditas Therapeutics (CALT) hat die bevorstehende Veröffentlichung seines Zwischenberichts für Q2 2024 (April - Juni) für Dienstag, den 13. August 2024, um 07:00 Uhr CET angekündigt. Der Bericht wird sowohl in Schwedisch als auch in Englisch verfügbar sein. Nach der Veröffentlichung wird das Unternehmen am gleichen Tag um 14:30 Uhr CET eine kombinierte Audioübertragung und Telefonkonferenz ausrichten.
Die Präsentation wird CEO Renée Aguiar-Lucander, CFO Fredrik Johansson, CMO Richard Philipson und Präsidentin Nordamerika Maria Törnsén umfassen. Die Teilnehmer haben während der Veranstaltung die Möglichkeit, Fragen zu stellen, die in Englisch durchgeführt wird. Interessierte können über einen Webcast oder einen Telefonanruf teilnehmen, wobei für Letzteres eine Registrierung erforderlich ist.
- None.
- None.
A combined audio cast and telephone conference with the opportunity to ask questions will be held at 14.30 p.m. CET on the same day, with CEO Renée Aguiar-Lucander and CFO Fredrik Johansson, CMO Richard Philipson and President North America Maria Törnsén.
The presentation will be given in English.
Link to the webcast:
https://ir.financialhearings.com/calliditas-therapeutics-q2-report-2024
To participate via conference call please register via this link:
https://conference.financialhearings.com/teleconference/?id=50049712
After registration, you will receive a phone number and a conference ID to log in to the conference call. Via the telephone conference, there is an opportunity to ask oral questions.
For further information, please contact:
Åsa Hillsten, Head of IR & Sustainability, Calliditas
Tel.: +46 76 403 35 43, Email: asa.hillsten@calliditas.com
The information was sent for publication, through the agency of the contact persons set out above, on August 5, 2024 at 7:00 a.m. CET.
This information was brought to you by Cision http://news.cision.com
The following files are available for download:
Invitation to the presentation of Calliditas_Q2 2024 ENG |
View original content:https://www.prnewswire.com/news-releases/invitation-to-the-presentation-of-calliditass-interim-report-january--june-2024-302214085.html
SOURCE Calliditas Therapeutics
FAQ
When will Calliditas Therapeutics (CALT) release its Q2 2024 interim report?
Who will present Calliditas Therapeutics (CALT) Q2 2024 results?
How can I participate in Calliditas Therapeutics (CALT) Q2 2024 earnings call?
What time is Calliditas Therapeutics (CALT) Q2 2024 earnings call?
